Full-Time

Director of Statistics

 Otsuka Pharmaceutical

Otsuka Pharmaceutical

1,001-5,000 employees

Global pharmaceutical company developing medicines

Compensation Overview

$186.5k - $278.9k/yr

+ Incentive Opportunity

Princeton, NJ, USA

In Person

Category
Biology & Biotech (2)
,
Required Skills
SAS
R
Machine Learning
biostatistics
Requirements
  • PhD in Biostatistics, Statistics, or a related field.
  • 8+ years of experience in biostatistics, including substantial expertise in health technology assessment (HTA), and supporting statistical and advanced analytics for Market Access, health economics and outcomes research (HEOR), and real-world evidence (RWE).
  • Deep familiarity with current HTA/regulatory frameworks (Bayesian, clinical/regional input for health economic models, consistent with FDA labeling or CFL is mentioned as CFL). Note: The text lists Bayesian, CFL, External Control, Covariates adjustment, Patient-Focused Drug Development, Enrichment, AI.
  • In-depth experience with indirect treatment comparisons such as matching-adjusted indirect comparison (MAIC), network meta-analysis (NMA), and clinical/regional input for health economic models
  • Proven experience in late-phase clinical trials and real-world studies in multiple therapeutic areas (Nephrology, CNS, Rare Disease is a plus but not required).
  • Knowledge of health economics, pricing and reimbursement, and HTA processes/guidance for global market access.
  • Strong expertise in statistical software packages, including R and SAS.
  • Excellent communication skills in explaining complex ideas, challenges, and solutions to leadership.
  • Proven ability to communicate complex statistical concepts effectively to both technical and non-technical stakeholders.
  • Leadership in effectively managing internal and/or vendor teams to deliver high quality results.
  • Leadership and mentoring experience, with the ability to work collaboratively in a cross-functional environment.
Responsibilities
  • Provide expert statistical guidance for late-phase clinical trials and real-world evidence (RWE) studies across programs including Nephrology, CNS and Rare Disease.
  • Lead statistical contributions to HTAs and Market Access submissions, ensuring that all statistical methodologies meet the necessary regulatory and reimbursement requirements.
  • Contribute to the development and implementation of HTA-related statistical methodologies, such as matching-adjusted indirect comparison (MAIC), Bayesian network meta-analysis and clinical/regional input for health economic models.
  • Ensure that analyses supporting CFL claims are scientifically appropriate and statistically sound (SASS). Lead or serve as the key point of contact on various statistics related initiatives.
  • Work closely with Global Value Evidence, Medical Affairs, Market Access, Regulatory, Clinical Management and Global Clinical Development teams to ensure alignment and successful execution of evidence generation strategies.
  • Provide statistical leadership in preparing evidence for HTA submissions and pricing/reimbursement strategies.
  • Collaborate with external vendors and partners to ensure the timely, high-quality delivery of statistical analyses and reports.
  • Lead the development and execution of statistical analysis plans (SAPs) and ensure the integrity and robustness of statistical analyses for clinical trials and real-world studies.
  • Lead the adoption of Bayesian frameworks to maximize data efficiency, specifically designing mechanisms to borrow information from historical trials or external control arms to support study designs and evidence generation.
  • Ensure consistency in statistical methods and analyses across therapeutic areas, particularly for Nephrology, CNS and Rare Disease.
  • Champion the application of machine learning (ML) and predictive modeling techniques to drive population enrichment strategies, identifying high-response patient subgroups to optimize late-phase and real-world study designs.
  • Facilitate Bayesian AI generative models for synthetic control arms and machine learning post-hoc analyses of clinical trials and real-world data (RWD).
  • Stay abreast of the latest developments in HTA, IEP, and statistical methodologies to ensure best practices and efficient approaches.
  • Provide mentorship and leadership to junior statisticians and other team members.
  • Contribute to the creation and maintenance of departmental SOPs and work instructions related to statistical methodologies.
  • Support training and knowledge-sharing within the organization on statistical methods, particularly in the context of HTA, market access, and real-world evidence.
  • Oversee the selection and management of external vendors, ensuring their work aligns with the organization’s standards and timelines.
  • Act as the primary statistical liaison in vendor collaborations, providing guidance and oversight to ensure that external analyses meet required standards.
 Otsuka Pharmaceutical

Otsuka Pharmaceutical

View

Otsuka Pharmaceutical is a global health-focused company that develops and markets medicines and nutraceutical products. It creates pharmaceuticals like Abilify (aripiprazole), an antipsychotic, and consumer health brands such as Pocari Sweat, an ion-replacement drink. Its products work by medical mechanisms (Abilify modulates dopamine and serotonin receptors to treat psychiatric conditions) and by supporting hydration and electrolyte balance (Pocari Sweat). Otsuka differentiates itself through a long, international growth path from its roots as a Japanese chemical manufacturer, a balanced portfolio spanning prescription drugs and health beverages, and a philosophy of developing new products to improve health worldwide. Its goal is to deliver healthier outcomes for people around the world by expanding access to innovative medicines and health-related consumer products.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1921

Simplify Jobs

Simplify's Take

What believers are saying

  • Voyxact achieves 82.5% hematuria improvement in IgAN trial at 48 weeks.
  • Acquired Transcend Therapeutics for $700M to advance psychiatric MDMA analog.
  • Partnered Keio University on May 8, 2025, for psychedelics infrastructure.

What critics are saying

  • AbbVie acquires Gilgamesh bretisilocin for $1.2B, leapfrogging Otsuka psychedelics.
  • Voyxact confirmatory trial fails kidney preservation in 18-24 months.
  • Japanese regulations block psychedelics trials in 24-36 months.

What makes Otsuka Pharmaceutical unique

  • Pioneered IV solutions in 1946, becoming Japan's top supplier.
  • Launched Pocari Sweat ion drink and Abilify antipsychotic globally.
  • Focuses on carbostyril-based original drugs since 1980.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Otsuka Pharmaceutical who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Company Match

Tuition Reimbursement

Student Loan Assistance

Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Dealroom.co
Mar 27th, 2026
Transcend Therapeutics company information, funding & investors

Transcend Therapeutics, developing the next generation of psychoactive compounds for neuropsychiatry focused on patient access. Here you'll find information about their funding, investors and team.

Fierce Biotech
Mar 27th, 2026
Otsuka buys Transcend Therapeutics for $700M upfront in psychiatric drugs deal

Otsuka Pharmaceutical has acquired Transcend Therapeutics for $700 million upfront through its subsidiary Otsuka America, with potential milestone payments of up to $525 million. The deal gives Otsuka access to Transcend's MDMA analogue for psychiatric conditions currently in development.

The Associated Press
Mar 25th, 2026
Otsuka's Voyxact shows 82.5% hematuria improvement in IgA nephropathy trial at 48 weeks

Otsuka presented new Phase 3 VISIONARY trial data for VOYXACT (sibeprenlimab-szsi) in IgA nephropathy patients at the 2026 ISN World Congress of Nephrology. The analyses showed 82.5% of patients receiving sibeprenlimab achieved negative microscopic hematuria at week 48, compared with 52.6% on placebo. Median time to achieve hematuria negativity was nine weeks versus 24 weeks for placebo. VOYXACT, approved under accelerated approval in the US, is a monoclonal antibody that inhibits APRIL, a key driver in IgAN pathogenesis. Previously reported data showed the drug met its primary endpoint with a 51.2% placebo-adjusted reduction in proteinuria at nine months. The trial continues evaluating sibeprenlimab's effect on preserving kidney function over 24 months.

Business Wire
Mar 2nd, 2026
Paradise ultrasound renal denervation system now covered by insurance in Japan for resistant hypertension

Otsuka Medical Devices and Otsuka Pharmaceutical have launched the Paradise Ultrasound Renal Denervation system in Japan, with National Health Insurance coverage effective 1 March. The device, developed by US subsidiary Recor Medical, treats resistant hypertension by reducing sympathetic nerve overactivity surrounding renal arteries. The system targets patients whose blood pressure remains above target despite using three different antihypertensive medications, including a diuretic. This marks Japan's first ultrasound renal denervation treatment. The Paradise system received FDA approval in the US in November 2023. Under a co-promotion agreement, both Otsuka companies will leverage their cardiovascular and renal expertise to deliver the treatment according to guidelines established by Japanese medical societies. The system offers a new option for resistant hypertension patients at high risk of serious cardiovascular complications.

The Associated Press
Feb 6th, 2026
Sky Labs secures exclusive deal with Otsuka Pharmaceutical to launch ring-type blood pressure monitor in Japan

Sky Labs has signed an exclusive distribution agreement with Otsuka Pharmaceutical to launch its ring-type blood pressure monitor, CART BP pro, in Japan's hospital and clinic market. The deal follows an MoU signed in December 2024. CART BP pro uses photoplethysmography technology to measure blood pressure without a cuff, allowing comfortable monitoring during daily activities and sleep. The device has already achieved success in South Korea, with over 150,000 prescriptions across 1,700 medical institutions since its 2023 approval and national health insurance coverage in 2024. Japan's hypertension market includes approximately 43 million patients, with 29% failing to achieve blood pressure control and 33% unaware of their condition. Sky Labs will leverage Otsuka's distribution network and cardiovascular expertise to expand across Japanese healthcare facilities.